<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363636</url>
  </required_header>
  <id_info>
    <org_study_id>114-NH-301</org_study_id>
    <nct_id>NCT00363636</nct_id>
  </id_info>
  <brief_title>A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind Study of Galiximab in Combination With Rituximab Compared With Rituximab in Combination With Placebo for the Treatment of Subjects With Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, multicenter, global, clinical study of an investigational drug called
      galiximab in combination with an approved drug called rituximab in subjects with follicular
      NHL.

      The purpose of the study is to compare the clinical benefit of galiximab when given in
      combination with rituximab as compared with rituximab alone (given with placebo) in subjects
      with follicular NHL. Safety and pharmacokinetics (PK) of galiximab and rituximab will also be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment challenges due to changes in standards of care resulted in premature termination. No
    safety or efficacy events factored into this action.
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess efficacy as measured by progression free survival (PFS), and determine whether rituximab plus galiximab compared to rituximab plus placebo may extend PFS.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy measures include: event-free survival, time to progression, duration of response, complete response rate, and overall survival.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures include: adverse event rates, clinical laboratory results, development of anti-galiximab and human anti-chimeric antibodies.</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using both the Functional Assessment of Cancer Therapy-Lymphoma (FACT-lym) and the EQ-5D (EuroQoL) instruments</measure>
    <time_frame>The duration of this study is approx 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">340</enrollment>
  <condition>Lymphoma, Non-Hodgkin's</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galiximab in combination with rituximab</intervention_name>
    <description>Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab in combination with placebo</intervention_name>
    <description>Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        Key Inclusion Criteria:

          -  Aged &gt;= 18 years old at the time of informed consent.

          -  Histologically confirmed follicular Grade 1-3a NHL.

          -  Relapsed or progressive disease after at least 1 prior chemotherapy requiring
             treatment.

          -  Bidimensionally measurable disease with at least 1 lesion &gt;= 2.0 cm in a single
             dimension.

          -  Acceptable hematologic, hepatic, and renal function parameters.

          -  Recovered fully from any significant toxicity associated with prior surgery, radiation
             treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell
             transplant, or investigational drugs.

        Key Exclusion Criteria:

          -  Follicular lymphoma Grade 3b.

          -  Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to
             prior rituximab or prior rituximab-containing regimen, or a response with a TTP of
             less than 6 months).

          -  Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to Study
             Day 1 (6 weeks if nitrosourea or mitomycin C).

          -  Prior lymphoma vaccine therapy within 12 months prior to Study Day 1.

          -  Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months
             prior to Study Day 1.

          -  Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1.

          -  Prior allogeneic transplant.

          -  Transfusion-dependent subjects.

          -  Another primary malignancy requiring active treatment (except hormonal therapy).

          -  Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active
             uncontrolled bacterial, viral, or fungal infections; or other conditions, which would
             compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

          -  New York Heart Association Class III or IV cardiac disease or myocardial infarction
             within 6 months prior to Study Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <disposition_first_submitted>September 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 2, 2015</disposition_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed</keyword>
  <keyword>NHL</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>antibody</keyword>
  <keyword>safety</keyword>
  <keyword>galiximab</keyword>
  <keyword>efficacy</keyword>
  <keyword>rituximab</keyword>
  <keyword>refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

